Description
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon2.,
Disease:Adenocarcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-BTN3A2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
BTN3A2 also known as Butyrophilin Subfamily 3 Member A2 is a protein involved in the immune response. It has a molecular weight of approximately 35 kDa. BTN3A2 expresses in a variety of tissues especially in immune-related cells like T-cells. It forms part of the butyrophilin family known for modulating immune cell functions. The protein is anchored in the cell membrane indicating its role in cell signaling.
Biological function summary
BTN3A2 participates in immune regulation and modulation of T-cell activity. It functions as part of the BTN3A family complex working alongside BTN3A1 and BTN3A3. This protein family influences T-cell receptor signaling and activation contributing to the immune system's ability to respond to pathogens and infections. BTN3A2 plays a role in linking extracellular and intracellular signals that affect immune cell behavior.
Pathways
BTN3A2 integrates within the adaptive immune signaling pathways. One key pathway is the T-cell receptor signaling pathway where BTN3A2 collaborates with BTN3A1 to modulate immune responses. Another significant involvement is in the gamma delta T-cell activation pathway. BTN3A2 partners with proteins like phosphoantigens and other butyrophilins emphasizing its role in controlling T-cell mediated immune functions.
BTN3A2 relates to certain autoimmune conditions and cancers. Altered expression of BTN3A2 connects to disorders like psoriasis where dysregulated immune activity plays a part. The protein also connects to chronic lymphocytic leukemia as abnormal BTN3A2 signaling could drive leukemic T-cell behavior. Through these diseases BTN3A2 associates with related proteins such as BTN3A1 and histone deacetylases interacting in pathways disrupted in these conditions.
